Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian Pharma Stocks 

Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.

Now or Never: Access Details of the No. 1 Small Cap Stock of 2020
» Result Scoreboard | Best Performing Stocks | Refresh
SCRIP BSE PRICE (Rs) NSE PRICE (Rs) CHART MORE INFO
AARTI DRUGS 518.35 2.48% 520.00 3.52%
 More Info 
AJANTA PHARMA 1,326.10 -2.94% 1,370.00 0.27%
 More Info 
ALEMBIC PHARMA 536.80 0.59% 531.00 -0.61%
 More Info 
BIOCON 278.00 2.73% 278.15 2.81%
 More Info 
CADILA HEALTHCARE 262.90 -1.57% 262.00 -1.96%
 More Info 
CIPLA 413.05 -2.35% 413.80 -2.14%
 More Info 
DIVIS LABORATORIES 1,886.00 -5.11% 1,894.00 -4.78%
 More Info 
DR. REDDYS LAB 3,100.00 -0.55% 3,102.00 -0.60%
 More Info 
GLENMARK PHARMA 203.65 -1.16% 203.90 -0.95%
 More Info 
INDOCO REMEDIES 197.00 -5.90% 199.00 -5.42%
 More Info 
IPCA LABS 1,392.70 0.33% 1,385.00 -0.52%
 More Info 
J.B.CHEMICALS 500.00 -1.64% 503.00 -1.18%
 More Info 
LUPIN 579.70 -1.70% 580.60 -1.53%
 More Info 
NATCO PHARMA 499.35 -1.34% 496.00 -1.89%
 More Info 
NIFTY 50 Not Listed 8,263.60 -3.89%
 More Info 
ORCHID PHARMA LTD 5.25 -4.89% 18.90 -2.83%
 More Info 
PANACEA BIOTECH 114.20 4.29% 115.10 5.35%
 More Info 
PIRAMAL ENTERPRISES 932.50 -0.67% 935.00 -0.48%
 More Info 
S&P BSE SENSEX 28,265.31 -4.08% Not Listed
 More Info 
STRIDES PHARMA SCIENCE 322.05 -0.16% 322.05 -0.03%
 More Info 
SUN PHARMA 344.50 -2.19% 344.95 -2.09%
 More Info 
TORRENT PHARMA 1,959.15 -0.63% 1,955.50 -0.83%
 More Info 
WOCKHARDT 178.80 3.50% 177.50 2.81%
 More Info 

BSE prices: April 1, 2020  03:35:00 PM    NSE prices: April 1, 2020  3:30:00 PM

Indian Pharma Stocks Update

The NIFTY PHARMA Index was at 7,043.4 (down 1.9%). The index is down 31.6% over the last 30 days. And over the last 1 year, it has lost 25.0%.

Within the Indian Pharma sector, the top gainers were PANACEA BIOTECH (up 4.3%) and WOCKHARDT (up 3.5%). On the other hand, INDOCO REMEDIES (down 5.9%) and DIVIS LABORATORIES (down 5.1%) were among the top losers.

Meanwhile, the benchmark NIFTY 50 was at 8,263.6 (down 3.9%).


What else is happening in the markets today? Dig in...



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Apr 1, 2020 03:35 PM

COMPARE COMPANY

MARKET STATS